Chronic Kidney Disease Market Report Scope & Overview:

The Chronic Kidney Disease Market size was valued at USD 40.22 billion in 2025E and is projected to reach USD 61.66 billion by 2033, growing at a CAGR of 5.51% during 2026-2033.

The global chronic kidney disease market is growing significantly due to increasing awareness and early diagnosis initiatives. Public health campaigns and government programs are expanding CKD screening among high-risk populations. Advanced diagnostic tools, including improved blood and urine testing, are boosting early detection rates. This chronic kidney disease market trend highlights a shift toward preventive healthcare, encouraging timely treatment interventions that slow disease progression, reduce complications, and ultimately improve patient quality of life.Top of Form

For instance, in March 2025, the International Society of Nephrology (ISN) reported that over 850 million people globally now live with kidney disease, but only 10% are diagnosed early, highlighting the push for expanded screening programs.

To Get More Information On Chronic Kidney Disease Market - Request Free Sample Report

Market Size and Forecast:

• Market Size in 2025: USD 40.22 billion

• Market Size by 2033: USD 61.66 billion

• CAGR: 5.51% from 2026 to 2033

• Base Year: 2025

• Forecast Period: 2026–2033

• Historical Data: 2022–2024

Chronic Kidney Disease Market Trends

• Rising prevalence of diabetes, hypertension, and obesity is driving demand for CKD diagnostics and treatments, especially for early detection and management of disease progression.

• Recent advancements in blood and urine biomarkers, including eGFR, cystatin C, and albuminuria testing, are enabling more sensitive and accurate diagnosis of CKD at earlier stages.

• Personalized medicine and precision therapies are emerging, with integration of SGLT2 inhibitors, GLP-1 receptor agonists, and targeted genetic therapies to tailor treatment based on patient profile.

• The increase in dialysis centers and availability of home-based dialysis solutions is enhancing access to treatment and improving patient convenience, especially in emerging markets.

• Government initiatives, screening programs, and reimbursement policies are expanding awareness and affordability of CKD management in both developed and developing countries.

• R&D collaborations between pharmaceutical companies, medical device firms, and research institutions are accelerating the development of innovative drugs and digital nephrology solutions.

• Trends toward tele-nephrology, digital monitoring, and AI-based predictive analytics are improving patient engagement, treatment adherence, and early intervention in CKD management.

U.S. Chronic Kidney Disease Market Insights

The U.S. Chronic Kidney Disease Market size was valued at USD 13.23 billion in 2025E and is projected to reach USD 20.16 billion by 2033, growing at a CAGR of 5.43% during 2026-2033. The US dominates the chronic kidney disease market due to the high prevalence of diabetes, hypertension, and obesity, which significantly drive CKD cases. A strong healthcare infrastructure with advanced diagnostics, established dialysis networks, and transplant facilities ensures widespread access to treatment. Robust pharmaceutical presence, heavy R&D investments, and government reimbursement programs support innovation and affordability. These factors, combined with early adoption of novel therapies, position the US as the largest and most influential CKD market globally.

Chronic Kidney Disease Market Growth Drivers:

• Expansion of Dialysis & Transplant Services Driving Chronic Kidney Disease Consumption Growth

Expansion of dialysis and transplant services is a major driver of the chronic kidney disease market, as rising global demand has pushed healthcare providers to increase capacity. The growing number of dialysis centers, adoption of home-based and portable dialysis, and improved transplant facilities are enhancing treatment accessibility. Government programs and private investments are supporting this expansion, ensuring more patients receive life-saving therapies, thereby driving strong market growth and improving patient survival outcomes.

For instance, in May 2025, Fresenius Medical Care surpassed 5,000 dialysis clinics globally, serving over 350,000 patients, underscoring rising global demand for dialysis services in chronic kidney disease.

Chronic Kidney Disease Market Restraints:

• Limited Organ Availability Limits Market Expansion Globally

Limited organ availability is a major restraint in the chronic kidney disease market, as the demand for kidney transplants far exceeds supply globally. Despite being the most effective treatment for end-stage renal disease, long waiting lists leave many patients dependent on dialysis. According to transplant associations, thousands die each year while awaiting a donor. This gap between need and availability significantly limits treatment accessibility and slows overall market growth potential in transplantation services.

Chronic Kidney Disease Market Opportunities:

• Growth Potential in Developing Countries with Increasing Healthcare Infrastructure Creates Growth Opportunities for the Chronic Kidney Disease Market

The growing healthcare infrastructure in developing countries presents a significant opportunity for the chronic kidney disease market. Rising urbanization, increased government investment in hospitals & Clinics, and dialysis centers, and expanding access to diagnostic facilities are improving CKD detection and treatment. As awareness grows, more patients can access timely interventions, including dialysis and transplantation. This development not only enhances patient outcomes but also creates a rapidly expanding market for CKD therapeutics, devices, and monitoring solutions.

For instance, in June 2024, the World Bank reported a 12% increase in Southeast Asia’s healthcare spending, boosting CKD diagnostic and treatment infrastructure across the region.

Chronic Kidney Disease Market Segmentation Analysis

• By diagnosis, blood test led the chronic kidney disease market with a 49.82% share in 2025e, while the urine test is the fastest-growing segment with a CAGR of 6.12%.

• By treatment, the drugs segment dominated the market with a 44.89% share in 2025e, whereas the kidney transplant segment is expected to grow fastest with a CAGR of 6.22%.

• By indication, type 1 or type 2 diabetes led the market with a 40.87% share in 2025e, while polycystic kidney disease is registering the fastest growth with a CAGR of 6.22%.

• By end user, hospitals & clinics held a 67.85% share in 2025e, while diagnostic centers are growing the fastest with a CAGR of 5.77%.

By End User, Hospital & Clinics Lead, While Diagnostic Centers Grow Fastest

The hospital & clinics segment accounted for the largest share of the chronic kidney disease market at around 67.85% in 2025E, as primary centers for diagnosis, dialysis, transplantation, and drug administration. This driving factor, supported by advanced infrastructure and comprehensive patient care, ensures widespread treatment access and continuous market growth globally. The diagnostic centers segment will have the highest CAGR of nearly 5.77% during 2026–2033, due to increasing demand for early detection and routine screening. This driving factor, supported by advanced testing technologies, enhances accessibility and accelerates market adoption globally.

By Diagnosis, Blood Test Leads the Market, While Urine Test Registers the Fastest Growth

The blood test segment dominated the chronic kidney disease market with a revenue share of about 49.82% in 2025E, as they provide accurate, early detection through markers like eGFR and creatinine. This driving factor enables timely intervention, improves patient outcomes, and supports growing demand for preventive CKD diagnostics globally. The urine test segment will grow at the highest CAGR of nearly 6.12% CAGR between 2026 and 2033, due to its effectiveness in detecting proteinuria and albuminuria early. This driving factor supports widespread screening, early intervention, and increased adoption in primary care and emerging markets.

By Treatment, Drugs Dominate While Kidney Transplants Show Rapid Growth

The drugs segment was estimated to be the largest revenue generator with an approximate 44.89% of the total market share in 2025E, owing to widespread use of SGLT2 inhibitors, ACE inhibitors, ARBs, and anemia therapies. This driving factor enables effective disease management, slows progression, and meets growing demand for personalized CKD treatment globally. For instance, the kidney transplant segment is anticipated to be the fastest growing with a CAGR of around 6.22%, by 2026-2033, due to advancements in surgical techniques, immunosuppressive therapies, and donor programs. This driving factor increases treatment accessibility and patient survival, fueling market expansion globally.

By Indication, Type 1 Or Type 2 Diabetes Leads, While Polycystic Kidney Disease Registers Fastest Growth

The Type 1 or Type 2 diabetes segment accounted for the highest share of revenues in the chronic kidney disease market at 40.87% in the year 2025E, as they are the leading causes of CKD. This driving factor, coupled with rising diabetes prevalence globally, increases demand for early detection, monitoring, and effective CKD management therapies. While the serology tests platforms segment is expected to achieve the fastest CAGR of approximately 6.22% during the predicted period from 2026-2033, due to increased genetic screening and awareness. This driving factor enables early diagnosis and targeted therapies, boosting treatment adoption and market growth globally.

Chronic Kidney Disease Market Regional Analysis:

North America Chronic Kidney Disease Market Insights

North America dominates the chronic kidney disease market with a market share of 38.60% 2025E, due to a high prevalence of diabetes, hypertension, and obesity, which drive CKD cases. Advanced healthcare infrastructure ensures early diagnosis through routine blood and urine testing, while widespread dialysis centers and transplant programs improve treatment access. Strong pharmaceutical presence, robust R&D investment, and government reimbursement policies further support innovation and patient affordability, making the region the largest and most influential CKD market globally.

Get Customized Report as Per Your Business Requirement - Enquiry Now

U.S. Chronic Kidney Disease Market Insights

The US dominates the North American CKD market due to high disease prevalence, advanced healthcare infrastructure, extensive dialysis and transplant networks, strong pharmaceutical presence, and supportive government reimbursement policies, ensuring widespread access to early diagnosis, treatment, and innovative therapies.

Asia-Pacific Chronic Kidney Disease Market Insights

Asia-Pacific is the fastest-growing region in the chronic kidney disease market, registering a CAGR of 6.40 % over the forecast period, due to rising prevalence of diabetes, hypertension, and obesity, coupled with increasing urbanization and lifestyle changes. Expanding healthcare infrastructure, government-led screening programs, and growing awareness of CKD are driving early diagnosis and treatment adoption. Rising investments by private players in dialysis centers, advanced diagnostics, and tele-nephrology solutions further accelerate growth. Additionally, emerging markets like India, China, and Southeast Asia are witnessing increased patient access to innovative therapies, fueling rapid market expansion across the region.

China Chronic Kidney Disease Market Insights

China is emerging as a key driver in the Asia-Pacific CKD market due to rising diabetes and hypertension prevalence, expanding healthcare infrastructure, government screening initiatives, and increasing access to dialysis, transplantation, and advanced CKD therapies across urban and rural populations.

Europe Chronic Kidney Disease Market Insights

Europe is the second-largest chronic kidney disease market due to a high prevalence of diabetes, hypertension, and aging populations. Advanced healthcare infrastructure, widespread access to dialysis centers and transplant programs, and strong government reimbursement policies support early diagnosis and effective treatment. Additionally, increasing awareness campaigns, routine screening programs, and ongoing R&D investments in CKD therapies and diagnostics contribute to sustained market growth, making Europe a significant player globally.

Germany Chronic Kidney Disease Market Insights

Germany is a key contributor to the European CKD market due to high CKD prevalence, advanced healthcare infrastructure, well-established dialysis and transplant networks, strong government support for screening programs, and widespread adoption of innovative therapies and diagnostics.

Latin America (LATAM) and Middle East & Africa (MEA) Chronic Kidney Disease Market Insights

Latin America and the Middle East & and Africa are emerging markets in the chronic kidney disease share. Rising prevalence of diabetes, hypertension, and obesity drives CKD incidence, while urbanization and lifestyle changes increase demand for treatment. Limited but growing healthcare infrastructure, expanding dialysis centers, and government initiatives for early diagnosis and awareness programs are supporting market growth. Investments in advanced diagnostics and therapies further enhance accessibility and treatment adoption across these regions.

Chronic Kidney Disease Market Competitive Landscape:

Fresenius Medical Care AG & Co. KGaA – Headquartered in Bad Homburg, Germany, and founded in 1996, Fresenius is a global leader in dialysis services and CKD management, providing dialysis machines, consumables, and comprehensive patient care solutions across more than 50 countries.

• In March 2025, Fresenius expanded its dialysis network in Asia-Pacific, opening 50 new centers across India and Southeast Asia, increasing patient access to CKD treatments and home-based dialysis options.

DaVita Inc. – Founded in 1994 and headquartered in Denver, Colorado, USA, DaVita operates a large network of dialysis centers, offering in-center and home-based dialysis treatments, renal care services, and patient support programs in North America and internationally.

• In August 2024, DaVita launched a tele-nephrology platform in the U.S. to remotely monitor CKD patients, improving early detection, treatment adherence, and personalized care management.

Baxter International Inc. – Headquartered in Deerfield, Illinois, USA, and established in 1931, Baxter provides renal care products, including dialysis machines, consumables, and CKD-related therapies, serving hospitals, clinics, and home dialysis patients globally.

• In November 2024, Baxter introduced its next-generation home dialysis machine in Europe and North America, enhancing ease of use, patient safety, and treatment flexibility for CKD patients.

Chronic Kidney Disease Market Key Players:

Some of the chronic kidney disease market Companies are:

• Fresenius Medical Care AG & Co. KGaA

• DaVita Inc.

• Baxter International Inc.

• B. Braun Melsungen AG

• Nipro Corporation

• Medtronic plc

• ImmunoGen, Inc. 

• Roche Holding AG 

• AstraZeneca plc

• GlaxoSmithKline plc

• AbbVie Inc.

• Amgen Inc. 

• Sanofi S.A. 

• Johnson & Johnson

• Mallinckrodt Pharmaceuticals

• Sumitomo Pharma Co., Ltd.

• Terumo Corporation

• Hospira 

• Vifor Pharma

• Shire